3American Diabetes Association. Implication of theUnited Kingdom Prospective Diabetes Study. Diabetes Care, 1998, 21∶2180-2185.
4O'Brien SV, Mangnall M, McNulty S,et al. Metformine superior to gliclazid whenused in combination with NPH insulin in type 2 diabetic patients inadequately controlledon oral Hypoglycemic therapy-Median Follow-up 13 months. Diabetes,1999,48(Suppl)∶A115.
5Yki-Jarvinen H, Vehkvaara S, Makimattila S, et al. Effect of 6 months of insulintherapy, acute hyperglycemia on endothlial function in type 2 diabetes. Diabetes, 1999，48(Suppl)∶A133.
6Mudaliar S, Mohideen P, Joyce M, et al. Pharmacokinetics and pharmacodynamics of85/15 premixed insulin compared to NPH and a 70/30 premixed insulin using the euglycemicclamp model. Diabetes,1999,48 (Suppl)∶A107.
7Dea MK, Hamilton-Wessler M, Ader M,et al.Albumin binding of long-acting insulinanalog ( NN304 ) slows plasma clearance, but does not deter action on glucose uptake inintestitial fluid. Diabetes,1999,48 (Suppl)∶A109.
8Cohen M. Use of lispro insulin in pregnancy : a 2 year experience.Diabetes,1999,48 (Suppl)∶A468.
9Allaudeen H, Ramaswamy M, Radhakrishnan B, et al. Orally active insulin: a singleinsulin conjugate selected for futur studies. Diabetes,1999,48 (Suppl)∶A105.
10Gerber RA, Cappelleri JC, Kourides IA, et al. Improved patient satisfaction withinhaled insulin in subjects with type 1 DM: results from a multicenter randomizedcontrolled trial. Diabetes,1999,48 (Suppl)∶A13.
（收稿：2000-01-14）
